Biotech Values

[DewDiligence]

XOMA sells 8.7M* shares @$3.62/sh, raising $29.7M* in net proceeds:

http://finance.yahoo.com/news/xoma-announces-pricing-27-5-123031775.html

The financing transaction was fully expected (#msg-90794646), but I figured XOMA would opt for a somewhat larger offering. After this raise, XOMA may not have enough cash to see the EYEGUARD uveitis program to completion while also running Gevokizumab PoC trials in other indications.

*Assuming exercise of underwriter’s option.